Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
137 hedge funds and large institutions have $1.7B invested in Acceleron Pharma in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 28 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 41
16% more capital invested
Capital invested by funds: $1.47B → $1.7B (+$229M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
8% less funds holding
Funds holding: 149 → 137 (-12)
17% less call options, than puts
Call options by funds: $4.92M | Put options by funds: $5.96M
39% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.7M |
| 2 |
BlackRock
New York
|
+$16.3M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$8.39M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.27M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$30.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.7M |
| 3 |
Millennium Management
New York
|
-$13.4M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$5.91M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$5.75M |
XLRN Hedge Fund Activity: Q4 2017 in Review
137 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2017, worth a combined $1.7B — up 16% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of XLRN and 17 opened new positions — a net loss of 11 holders — while 41 trimmed existing stakes and 49 added.
The largest buyer was Fidelity Investments, adding an estimated $51.7M. The largest seller was Citigroup, cutting an estimated $30.3M.
- 137 institutional investors held Acceleron Pharma (XLRN) as of Q4 2017, down from 149 in Q3 2017.
- Funds reported $1.7B of Acceleron Pharma stock for Q4 2017, up 16% quarter-over-quarter.
- 17 funds opened new Acceleron Pharma positions in Q4 2017 and 28 closed out, a net change of -11 holders.
- The largest Acceleron Pharma buyer in Q4 2017 was Fidelity Investments, an estimated $51.7M added.
- The largest Acceleron Pharma seller in Q4 2017 was Citigroup, an estimated $30.3M sold.
Based on aggregated 13F filings for Q4 2017.